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Schizophrenia is a severely debilitating form of mental 
illness that affects 1% of the global population. Patients 
exhibit symptoms that include hallucinations and delu­
sions (known as positive symptoms), avolition and reduced 
affect (known as negative symptoms) as well as cognitive 
deficits (BOX 1). The diversity of these clinical symptoms, 
and the fact that they overlap with symptoms present in 
other forms of mental illness such as bipolar disorder, 
raises questions about the future classification and diag­
nosis of neuropsychiatric disorders in general. Research 
suggests that schizophrenia results from a combination 
of genetic, neurodevelopmental and environmental risk 
factors1,2. However, our ability to diagnose schizophrenia 
— based on biomarkers that reflect causal genetic, bio­
chemical and pathophysiological events — is in its infancy. 
Schizophrenia is usually diagnosed in late adolescence or 
early adulthood, and patients require medication through­
out their lives. Existing medications — which primarily 
target dopamine receptors — do not cure the disease, fail 
to alleviate many of the symptoms of the disorder and have 
many serious side effects. Hence, new improved therapies 
are urgently required. Understanding the complex neuro­
biology underlying the ‘troubled mind’ in schizophrenia is 
key to the development of new treatments.
Antipsychotic drugs have been the mainstay of schizo­
phrenia treatment for several decades. The introduction 
of chlorpromazine in the 1950s revolutionized the treat­
ment of the disorder; however, it was not until the 1970s 
that advances were made in the understanding that the 
binding affinity of antipsychotic drugs to the dopamine 
D2 receptor subtype correlated with their clinical efficacy 
in alleviating hallucinations and delusions. At the neu­
ronal level, these drugs are thought to block dopamine 
receptors in the mesolimbic dopaminergic system to 
alleviate the psychotic (positive) symptoms. An unfor­
tunate consequence of this is that dopamine blockade 
in the nigrostriatal and hypothalamic–pituitary systems 
results in unwanted side effects resembling Parkinson’s 
disease (known as extrapyramidal side effects) and hyper ­
prolactinaemia, respectively. 
This profile, along with other side effects such as 
sedation and hypotension, led to the development of 
other therapeutic strategies, including the development 
of agents targeting specific dopamine receptor subtypes 
or a range of receptors (known as multi­affinity receptor 
target agents), as well as the development of compounds 
with a balance of activity against 5­hydroxytryptamine 
(5­HT; also known as serotonin) receptors versus D2 
receptors, with the hope of obtaining an improved thera­
peutic profile. The term ‘atypical drugs’ (also known as 
second­generation drugs) was introduced to suggest that 
these newer compounds were a substantial improvement 
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Advancing schizophrenia drug 
discovery: optimizing rodent models 
to bridge the translational gap
Judith Pratt1,2, Catherine Winchester1,2, Neil Dawson1,2 and Brian Morris2,3
Abstract | Although our knowledge of the pathophysiology of schizophrenia has 
increased, treatments for this devastating illness remain inadequate. Here, we critically 
assess rodent models and behavioural end points used in schizophrenia drug discovery 
and discuss why these have not led to improved treatments. We provide a perspective on 
how new models, based on recent advances in the understanding of the genetics and 
neural circuitry underlying schizophrenia, can bridge the translational gap and lead  
to the development of more effective drugs. We conclude that previous serendipitous 
approaches should be replaced with rational strategies for drug discovery in integrated 
preclinical and clinical programmes. Validation of drug targets in disease-based models 
that are integrated with translationally relevant end point assessments will reduce the 
current attrition rate in schizophrenia drug discovery and ultimately lead to therapies 
that tackle the disease process.
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Avolition
Generalized lack of motivation 
to perform tasks or undertake 
activities: probably linked to 
other negative symptoms such 
as social withdrawal and 
anhedonia (inability to take 
pleasure in activities). 
Reduced affect 
Loss of emotional 
responsiveness (for example, 
when talking); characteristic  
of schizophrenia and major 
depressive disorder. 
Construct validity
An animal model has construct 
validity when the experimental 
mechanisms used to create  
the model are related to the 
underlying mechanisms 
involved in disease aetiology. 
over the ‘typical’ older drugs, such as chlorpromazine 
and haloperidol, in terms of treating a broader range of 
symptoms and reducing their side­effect profile. Over 
time, the appropriate use of the term ‘atypical’ has become 
blurred; perhaps a clearer definition of drug ‘atypicality’ 
is that the drug has a similar efficacy to typical drugs 
but fewer extrapyramidal side effects. 
The various hypotheses concerning the mechanism 
of action of these drugs, from a receptor pharmacology 
perspective, are summarized in TABLE 1 and BOX 2 (also 
reviewed in REF. 3). Despite the abundance of proposed 
receptor­mediated mechanisms to explain drug atypi­
cality, all existing antipsychotic drugs target dopamine 
receptors to varying degrees. This commonality in mech­
anism of action underpins the dopamine hypothesis of 
schizophrenia. A considerable body of evidence supports 
the notion that the positive symptoms of schizophre­
nia are related, at least in part, to aberrant mesolimbic 
dopamine transmission, and can thus be ameliorated via 
antipsychotic drugs that block dopamine receptors4–6. 
Although it has been postulated that atypical drugs 
can treat all the symptoms of schizophrenia with fewer 
extrapyramidal side effects (because they have reduced 
effects on the nigrostriatal pathway compared to typical 
drugs), this notion has recently been challenged. The 
CATIE (Clinical Antipsychotic Trials in Intervention 
Effectiveness) studies7 demonstrated similar efficacy and 
extrapyramidal side­effect profiles for both typical and 
atypical drugs but there were some confounding issues 
related to dose selection. 
In essence, drug treatment for schizophrenia has not 
advanced substantially in the past 50 years. Nevertheless, 
advances have been made in understanding the poten­
tial role of other receptors (in addition to dopamine 
receptors) in contributing to drug efficacy, as well as the 
involvement of these receptors in specific side effects8,9. 
However, the view that all antipsychotic drugs need to 
produce a degree of D2 receptor blockade to be clini­
cally effective against psychotic symptoms remains a 
contentious topic.
Atypical antipsychotic drugs have a limited ability 
to improve cognitive deficits or negative symptoms. As 
these symptoms are the strongest predictors of long­
term functional outcome for patients10, they represent a 
large unmet therapeutic need. So where do we go next? 
Given that D2 receptor blockade does not ameliorate the 
negative symptoms and cognitive deficits associated with 
schizophrenia, much of the current opinion regarding 
which preclinical disease models could be useful for 
predicting clinical drug efficacy is erroneous. 
The development of new preclinical models for cogni­
tive deficits and negative symptoms is a major challenge 
as it relies on an understanding of the neurobiological 
processes that underpin these clinical symptoms and 
the ability to translate these into an equivalent animal 
model. Characterization of cognitive dysfunction in 
psychiatric diseases is therefore paramount to inform 
animal models11. Various initiatives and consortia have 
been set up to tackle this unmet clinical need (BOX 3). 
Specific consortia aim to ascertain which specific subsets 
of symptoms (or domains) are most amenable to mod­
elling in a preclinical context. These consortia include 
the MATRICS (Measurement and Treatment Research 
to Improve Cognition in Schizophrenia) and CNTRICS 
(Cognitive Neuroscience Treatment Research to Improve 
Cognition in Schizophrenia) initiatives. 
Other consortia are adopting multipronged appro­
aches for the discovery of new medicines (for example, 
NEWMEDS (Novel Methods Leading to New Medica tions 
in Depression and Schizophrenia), which is funded by 
the Innovative Medicines Initiative; see the NEWMEDS 
website) or they are evaluating the potential clinical 
efficacy of new compounds (for example, TURNS 
(Treat ment Units for Research on Neurocognition and 
Schizophrenia); see the TURNS website). Crucially, these 
consortia evaluate the robustness of laboratory tests and 
the reproducibility of results across sites. 
Strategies for drug discovery: keys to success
Two essential factors for developing new strategies for 
improved drug discovery in schizophrenia. First, the 
disease model should be based on known pathophysio­
logical, genetic and environmental risk factors — that is, 
it should have demonstrable construct validity. Second, 
the assays for the phenotypic assessment of the model 
should be translational. For example, the neurobiology 
underpinning the behaviour of interest should overlap in 
rodents and in humans. Clearly there are huge challenges 
Box 1 | Symptoms of schizophrenia
Schizophrenia was first described by Kraepelin and Bleuler at the turn of the twentieth 
century. It is typically classified into three broad clusters of symptoms that can be 
further subdivided into various domains and subdomains (or constructs). There is  
an evolving debate on which domains and/or subdomains are core to the disease, 
although the neurobiological mechanisms that underpin them are not completely 
understood. 
Positive symptoms. Positive symptoms consist of hallucinations (typically auditory)  
and delusions, and are amenable to drug therapy.
Negative symptoms. Negative symptoms encompass blunted affect, deficits in social 
functioning, anhedonia, avolition and poverty of speech. Avolition and diminished 
emotional expression are key negative symptom subdomains, whereas poverty  
of speech and inappropriate affect are more related to cognitive symptoms119. 
Avolition (lack of motivation) rather than anhedonia is likely to be a core symptom  
of the disorder as patients can experience pleasure even though their outward 
expression of emotions is reduced. Patients have a reduced capacity to anticipate 
whether the pursuit or achievement of a goal will be pleasurable. These symptoms  
are resistant to treatment.
Cognitive deficits. Cognitive deficits are arguably the most debilitating and enduring 
deficits in schizophrenia and remain resistant to treatment. Cognitive impairments 
occur in a range of neuropsychological tests; they are present in patients who  
have never been medicated and they are observed before the onset of psychosis, 
suggesting that they are core deficits of the illness120. Around 20–60% of the variance 
in functional recovery is explained by cognitive performance. Thus the potential  
to enhance functional outcome has been a major driver for developing novel 
treatments, and has led to the establishment of major initiatives to tackle this 
problem, such as the MATRICS (Measurement and Treatment Research to Improve 
Cognition in Schizophrenia) initiative and the CNTRICS (Cognitive Neuroscience 
Treatment Research to Improve Cognition in Schizophrenia) initiative. Cognitive 
symptoms include deficits in working memory, executive control, attention, 
long-term memory, perception and social cognition. Each of these cognitive 
domains can be subdivided into distinct subdomains (also known as constructs).
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Pyramidal cell 
A large neuron with a cell  
body roughly in the shape of  
a pyramid. These neurons use 
glutamate as their transmitter, 
and in many cases send fibres 
for considerably long distances 
to stimulate neurons in other 
parts of the brain. 
in modelling complex disorders such as schizophrenia, 
in which many components of the disease are uniquely 
observed in humans. Nevertheless, it is important to 
emphasize that a single model can have utility without 
fully recapitulating the disease.
By assessing compounds in translational assays using 
models with construct validity, the selection of potential 
clinically efficacious compounds in Phase I trials will 
be enhanced and the rate of attrition will be reduced 
as compounds progress along the drug discovery pipe­
line. Close integration of preclinical and clinical teams, 
along with appropriate consideration of key issues such 
as pharmacokinetic variables, is essential for these trans­
lational neuroscience strategies to be successful.
Below, we provide an overview of current and emerg­
ing pathophysiological and genetic models in the context 
of the assays used for drug discovery that putatively assay 
positive, negative and cognitive symptoms (for a critique 
of the assays, see BOXES 3,4).
Models based on the glutamate hypothesis
The glutamate hypothesis of schizophrenia has devel­
oped from the observation that administration of NMDA 
(N­methyl­d­aspartate) receptor antagonists — such as 
phencyclidine (PCP) and ketamine — induces a psy­
chosis in humans that closely resemble schizophrenia, 
encompassing the negative and positive symptoms of the 
disease as well as the cognitive deficits12,13. Furthermore, 
these drugs exacerbate symptoms in patients with schizo­
phrenia. Mechanistically, it is thought that acute NMDA 
receptor blockade leads to symptoms of schizophrenia 
by blocking tonically active NMDA receptors on GABA 
(γ­aminobutyric acid)­ergic interneurons, which in 
turn leads to the disinhibition of pyramidal cell firing. 
The resulting increase in glutamate release, particularly 
in the prefrontal cortex, is postulated to be linked to the 
behavioural deficits observed14,15. 
The relationship between the disruptive effects of 
acute ketamine administration on cognition in healthy 
volunteers and in patients with schizophrenia remains 
unclear. The picture is further confounded by the recent 
findings that ketamine appears to have antidepressant 
activity, potentially via modification of the mamma­
lian target of rapamycin (mTOR) pathway16. However, 
genetic and molecular analyses of post­mortem brain 
tissues also indicate that a dysfunctional glutamatergic 
system is implicated in schizophrenia. Robust observa­
tions include reduced expression of presynaptic proteins, 
such as vesicular glutamate transporter 1 (VGLUT1; 
also known as SLC17A7) together with synaptophysin, 
synaptotagmin and synaptosomal­associated protein 
25 kDa (SNAP25)17–19, along with altered postsynaptic 
glutamate receptor expression in both the prefrontal 
cortex and the hippocampus20. 
Table 1 | Receptor and side-effect profiles of a selection of antipsychotic drugs
Drug  Receptor affinity Side effects
D1 D2 α1-AR H1 mAChR 
(M1–M4) 
5-HT2A 5-HT6 5-HT7 EPS Sedation Hypotension Other
Typical antipsychotics
Haloperidol ++ ++++ ++ – – ++ – + *** ~ ** Minimal anti - 
cholin ergic side 
effects
Chlorpromazine ++ +++ +++ ++ ++ ++/+++ +++ ++ ** ** ** Anticholinergic side 
effects (dry mouth, 
constipation, blurred 
vision)
Thioridazine ++ ++/+++ +++ – ++/+++ ++ +++ ++ * ** ** Anticholinergic side 
effects (dry mouth, 
constipation, blurred 
vision) 
Atypical antipsychotics
Clozapine ++ + +++ +++ ++/+++ +++ +++ +++ ~ ** * Agranulocytosis (1%); 
regular blood counts 
required; salivation 
(M3-mediated?);  
weight gain
Olanzapine ++ +++ +++ +++ ++/+++ +++ +++ ++ * ** * Weight gain (5-HT
2C
 
mediated?)
Risperidone ++ +++ +++ + – ++++ + +++ * ** * Weight gain
Quetiapine ++ ++ +++ ++++ – ++ – – ~ ** * Weight gain
Aripiprazole + ++++ ++ ++ – +++ + +++ ~ * * Minimal weight gain 
–, minimal affinity (>1 μM); +, low affinity (101–1,000 nM); ++, moderate affinity (11–100 nM); +++, high affinity (1–10 nM); ++++, very high affinity (<1 nM);  
~, minimal side-effect profile; *, mild side-effect profile; **, moderate side-effect profile; ***, severe side-effect profile; α1-AR, α1-adrenergic receptor;  
5-HT
2A
, 5-hydroxytryptamine receptor 2A; D1, dopamine D1 receptor; EPS, extrapyramidal side effects; H
1
, histamine receptor H
1
; mAChR (M1–M4), muscarinic 
acetylcholine receptor subtypes M1–M4. 
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Genetic association and copy number variation stud­
ies are, at the very least, consistent with a causal role for 
glutamate synapse disruption in disease aetiology21,22. 
Thus there is compelling converging pathophysiologi­
cal and molecular evidence supporting the ‘glutamate 
hypofunction’ hypothesis of schizophrenia. To this end, 
NMDA receptor antagonists are widely used in preclini­
cal research for modelling aspects of schizophrenia. 
Over the past decade, many academic and commer­
cial groups have exploited NMDA receptor antagonist 
models in drug discovery (reviewed in REFS 23,24); 
below, we provide a synopsis of these studies, with 
emphasis on the translational capacity of the models and 
the impact that this has had on drug discovery. 
It is important to highlight that NMDA receptor antag­
onists have been used in numerous acute­ and repeated­
dosing regimens in drug discovery. Furthermore, some 
behavioural measures are taken in the presence of NMDA 
receptor antagonists, whereas others are taken following 
cessation of NMDA receptor treatment (which may 
have been administered in a vulnerable neurodevelop­
mental period or during adulthood). Not surprisingly, 
a plethora of data has emerged that has not produced a 
consistent picture or even provided clear predictive evi­
dence for compounds that have antipsychotic activity. 
Superimposed on this is the fact that numerous behav­
ioural phenotypes have been measured, several of which 
have a limited relationship to schizophrenia. The develop­
mental timing and nature of aberrant glutamate transmis­
sion is likely to be fundamental to this chronic disorder. 
Arguably, models that involve chronic NMDA receptor 
antagonist administration are most likely to correspond 
to the disease state, whereas acute models are most likely 
to represent acute psychotic states.
Compound evaluation in assays of potential relevance 
to positive symptoms. Many studies involving the 
acute dosing of NMDA receptor antagonists have used 
Box 2 | Treatments for schizophrenia
Existing treatments for schizophrenia were developed using preclinical models based on the dopamine hypothesis.  
The dopamine hypothesis of schizophrenia originated in the 1960s from the observations that psychostimulant drugs  
(for example, amphetamine), which enhance neuronal dopamine levels, can lead to psychotic symptoms that are almost 
indistinguishable from schizophrenia. The concept that antipsychotic drugs act by blocking dopamine D2 receptors has 
been put into the context of symptom alleviation by Kapur6. It is advocated that the normal role of dopamine in the 
mesolimbic pathway is to mediate the ‘salience’ of environmental events and internal representations. In schizophrenia  
the proposed hyperdopaminergic state may lead to a distortion of how the patient assigns relevance to a particular 
experience. It is posited that hallucinations may reflect the actual experience of attributing abnormal salience to internal 
representations, whereas delusions may be a cognitive effort by the patient to make sense of these abnormal experiences.
Antagonism of specific dopamine receptors
It has been argued that D2 receptor blockade could explain the clinical efficacy of both typical and atypical antipsychotic 
drugs121. However, this does not explain the fact that clozapine can improve positive symptoms at a lower D2 receptor 
occupancy (30–60%) than other drugs. D2 receptor blockade does not improve negative symptoms or cognitive deficits, 
as evidenced by the limited efficacy of existing drugs. D1 receptor antagonism in the prefrontal cortex may be important, 
particularly in the actions of clozapine. However, other receptors or combinations of receptors may also be key. 
Sulpiride and amisulpride are relatively selective for D2 and D3 receptors, with minimal affinity for α-adrenergic 
receptors, muscarinic acetylcholine receptors and 5-hydroxytryptamine (5-HT; also known as serotonin) receptor 
subtypes. Neither sulpiride nor amisulpride has an improved therapeutic profile over drugs that have a broader receptor 
profile. Other studies have suggested that D2 receptor occupancy and/or off rate may be an important determinant of 
drug efficacy (reviewed in REFS 122,123). 
Partial D2 receptor agonists
Aripiprazole, one of the more recently introduced atypical drugs, is considered to be a partial agonist of the D2 receptor. 
On this basis, it is posited to enhance dopamine activity in areas of the brain where there is a low dopaminergic tone, and 
inhibit activity where there is a high dopaminergic tone. With regard to schizophrenia, one hypothesis is that aripiprazole 
reduces the activity of the hyperactive mesolimbic dopaminergic neurons that mediate psychosis while simultaneously 
enhancing the activity of underactive mesocortical dopamine neurons that are proposed to be involved in the cognitive 
and negative symptoms of the disorder. Aripiprazole also acts as an antagonist of 5-HT
2
 receptors and a partial agonist of 
5HT
1A
 receptors124. 
Serotonin–dopamine ratio
The serotonin–dopamine antagonism theory proposed by Meltzer125 argues that drug ‘atypicality’ is conferred by a higher 
affinity of a drug for 5-HT
2A
 receptors relative to dopamine D2 receptors. Risperidone is an example of a drug that falls 
into this class (TABLE 1).
Multiple-affinity receptor target agents
Many atypical drugs have affinity for multiple receptors, including D1 receptors, D2 receptors, α1‑adrenergic receptors, 
muscarinic receptors and various 5‑HT receptor subtypes (TABLE 1). These drugs include clozapine, olanzapine, 
risperidone and quetiapine. However, these drugs bind differentially to these receptors. For example, olanzapine has a 
high affinity for most of these receptors, risperidone has a particularly high affinity for 5-HT
2A
 receptors, and quetiapine 
has a higher affinity for α-adrenergic receptors than for dopamine receptors123. Interestingly, many atypical drugs have 
affinity for 5-HT
6
 receptors; the hallucinogenic drug lysergic acid diethylamide (LSD) also binds to these receptors. 
However, it should be noted that many typical drugs also act on several receptors, and so the hypothesis that atypicality  
is based on multiple receptor targets does not hold.
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Prepulse inhibition 
(PPI). A reduction in the 
magnitude of the startle  
reflex that occurs when an 
organism is presented with  
a non-startling stimulus  
(a prepulse) before being 
presented with the startling 
stimulus. Deficits in PPI have 
been observed in patients with 
schizophrenia as well as in 
patients with other psychiatric 
and neurological disorders. 
Predictive validity
An animal model has predictive 
validity when predictions  
(for example, of drug efficacy) 
made using the model are 
informative for when an 
equivalent drug is used 
clinically in patients.
Attentional set-shifting task 
A task that is used for 
assessing rule learning and 
cognitive flexibility in rodents. 
Animals learn a set of 
stimulus–reward associations 
(for example, a particular 
odour associated with food 
reward) while simultaneously 
ignoring another stimulus (for 
example, texture). The rules 
are then changed such that 
texture is the salient stimulus. 
Intradimensional–
extradimensional shift 
A test of rule acquisition and 
reversal that is sensitive  
to frontostriatal regions. 
behavioural assays that were previously used for iden­
tifying dopamine antagonists when the dopamine 
hypothesis of schizophrenia prevailed. This derivative 
approach confirmed that ‘typical’ antipsychotic drugs 
such as haloperidol could reverse acute NMDA receptor 
antagonist­induced increases in locomotor activity and 
deficits in prepulse inhibition (PPI). 
Following the characterization of a broader range of 
drugs, it became apparent that compounds such as clo­
zapine, quetiapine and olanzapine were more effective 
at blocking PCP­induced PPI deficits than haloperidol. 
This, along with the reduced propensity of these drugs 
to induce catalepsy in rodents, led to the suggestion 
that these second­generation drugs were ‘atypical’ and 
may be clinically advantageous over ‘typical’ drugs. The 
introduction of several of these compounds (risperidone, 
olanzapine, quetiapine and ziprasidone) in the 1990s 
and early 2000s led to a wave of enthusiasm about their 
potential clinical advantages over the older typical drugs. 
Unfortunately, this enthusiasm has now been dispelled by 
the results of the CATIE studies7. Interestingly, the ability 
of antipsychotic drugs to restore PPI deficits in patients 
is not validated to the same extent as in preclinical stud­
ies. Furthermore, some NMDA receptor antagonists 
such as ketamine do not appear to produce PPI deficits 
in humans25, raising the possibility that these symptoms 
are not related to positive or cognitive symptom domains.
How have the aforementioned preclinical studies 
helped in drug discovery? In general, reversal of defi­
cits in PPI and locomotor activity (induced by the acute 
dosing of NMDA receptor antagonists) has shown some 
predictive validity in the identification of antipsychotic 
drugs. However, it is unclear whether the rescue of these 
behaviours by putative antipsychotic drugs in acute 
NMDA receptor antagonist models offers any advantage 
— namely, in the identification of compounds that have 
superior efficacy to typical drugs — over the rescue of 
these behaviours in traditional dopamine­related models. 
Compound evaluation in assays of putative relevance 
to negative symptoms. Antipsychotic drugs have been 
shown to restore PCP­induced deficits in social behav­
iour26. As current antipsychotic drugs are not clinically 
efficacious against negative symptoms, this assay does 
not show good predictive validity.
Compound evaluation in assays of relevance to cogni-
tive domains. The development of new drugs has been 
hampered by the lack (or minimal efficacy) of existing 
drugs for treating the cognitive deficits associated with 
schizophrenia; there is no gold­standard positive­control 
drug that can be used in cognitive assays. 
Other limiting factors include drug dosing regimens, 
the use of behavioural assessments that cannot be trans­
lated (or can only be partially translated) into the clinic 
as well as the insensitivity of some of the instrumen­
tation that is used to measure cognitive symptoms in 
patients with schizophrenia.
The ability of several atypical antipsychotic drugs 
to restore NMDA receptor antagonist­induced deficits 
in cognitive behavioural tasks, including novel object 
recognition, is in line with the limited translational rel­
evance of these assays and the false positives that are 
often generated27.
Cognitive behavioural tasks that show promise in a 
drug discovery context include the 5­choice serial reaction 
time task (5­CSRTT) and the attentional set-shifting task 
(ASST) (BOX 3). In the 5­CSRTT, clozapine has a limited 
ability to restore subchronic and chronic NMDA receptor 
antagonist­induced deficits in performance28, paralleling 
its limited efficacy in the clinic. Studies involving the acute 
dosing of NMDA receptor antagonists are confounded 
by the effects of both PCP and clozapine on locomotor 
activity, further emphasizing the importance of subchronic 
and chronic NMDA receptor antagonist models in drug 
discovery28,29. Nicotine and nicotinic acetylcholine recep­
tor α7 (α7 nAChR) agonists are effective at improving 
cognitive performance in the 5­CSRTT task. The limita­
tion of many studies using these translationally relevant 
end point measures is that these measures have gener­
ally not been applied to a disease model with construct 
validity. It is important to emphasize that the use of a 
translationally relevant assay in combination with a rel­
evant disease model will provide the greatest chance of 
success for drug discovery.
Compounds that act at the α7 nAChR have modest 
cognition­enhancing effects in cognitive tasks in naive 
(untreated) animals30, but their translation into the clinic 
is proving to be equivocal; although a proof­of­concept 
Phase I clinical trial of the α7 nAChR partial agonist 
DMXB­A (3­2,4 dimethoxybenzylidene) in patients with 
schizophrenia found that the drug improved neuropsy­
chological measures, a subsequent Phase II trial found 
no associated changes in cognition31,32.
Another drug of considerable interest is modafinil. 
Originally used as a wake­promoting agent for the treat­
ment of narcolepsy, emerging evidence from small­scale 
clinical trials shows that modafinil can improve cognitive 
deficits in patients with schizophrenia33,34. Specifically, 
modafinil reverses intradimensional–extradimensional 
deficits in the CANTAB (Cambridge Neuropsychological 
Test Automated Battery) test in patients. In parallel, 
modafinil restores subchronic PCP­induced deficits 
in the extradimensional–intradimensional shift in the 
rodent ASST35,36. Importantly, existing antipsychotic 
drugs have limited effects in this model. Together, these 
findings suggest that the restoration of subchronic PCP­
induced deficits in the ASST may have good predictive 
validity for assessing cognition­enhancing agents in 
schizophrenia.
Novel compounds such as phosphodiesterase inhibi­
tors and 5­HT6 receptor antagonists are also reported to 
have efficacy against PCP­induced extradimensional–
intradimensional deficits37,38, thus providing proof of 
principle that phosphodiesterases and the 5­HT6  recep­
tor are possible therapeutic targets. It should be empha­
sized however, that the ASST is preclinically very labour 
intensive. In addition, in some experiments that use the 
ASST, drugs have been claimed to be cognition enhancers 
but there has been no clear difference in the ability of 
control animals to complete the extradimensional shift 
relative to the intradimensional shift27. This suggests that 
R E V I E W S
564 | JULY 2012 | VOLUME 11  www.nature.com/reviews/drugdisc
© 2012 Macmillan Publishers Limited. All rights reserved
Box 3 | Behavioural assays: cognitive deficits
Translational assays that make use of analogous clinical processes and 
utilize similar neural circuitry are most likely to predict clinically relevant 
cognition-enhancing compounds. Moreover, the assay should distinguish 
between specific cognitive deficits and poor performance resulting from 
generalized deficits (for example, low motivation or sedation). Such assays, 
informed by cognitive neuroscience, allow valid translation from animals 
to humans and vice versa.
Although many preclinical assays are being used in drug discovery,  
few fit the above criteria; this imperfect construct validity implies that 
these assays have limited predictive validity. Here, we summarize those 
assays that more closely fit the cognitive neuroscience-informed CNTRICS 
(Cognitive Neuroscience Treatment Research to Improve Cognition in 
Schizophrenia) criteria (see REF. 27 for a detailed discussion on assays 
based on the broader MATRICS (Measurement and Treatment Research  
to Improve Cognition in Schizophrenia) recommendations). 
Attention
Attention can be divided into components such as divided and focused 
attention. Attentional deficits are present in schizophrenia, although the 
particular components that are most affected are still under debate. At a 
CNTRICS meeting, assays that incorporate the control of attention were 
nominated as having the greatest promise for clinical studies129. 
The 5-choice serial reaction time task (5-CSRTT), sustained attention task 
and the lateralized reaction time task are well-characterized tasks that 
are performed in rodents for measuring attention130. The 5-CSRTT is of 
particular interest because of its similarities with the continuous 
performance task, which is performed in humans. The 5-CSRTT is a 
visuospatial attention assay in which animals have to divide their attention 
on a sustained basis (via visual search) in order to detect brief visual target 
stimuli (lights) presented randomly in one of five locations (apertures) 
over a large number of trials. The task can also incorporate elements of 
increased attentional demand as well as inhibitory control (animals have  
to withhold responses under certain conditions). 
The task provides comprehensive measures of attention and inhibitory 
control (premature responding) together with measures of processing 
speed, motor effects and cognitive flexibility (for example, perseveration). 
Assessing a range of cognitive components (constructs) is advantageous  
in studying potential cognition enhancers as it enables the isolation of 
specific constructs, as well as possible adverse effects, to be identified in  
a single test. The tasks in both humans and animals involve the prefrontal 
cortex and thalamus, although the precise brain circuitry involved is not 
completely identical between humans and animals. Nevertheless, the 
5-CSRTT demonstrates considerable construct validity.
Executive control
Executive control is an umbrella term for an array of higher-order 
processes. Deficits in executive control can affect performance in other 
tasks including those that measure attention and working memory.  
The ‘rule learning and selection’ elements of executive control can be 
assessed by the intra- and extradimensional (ID–ED) set-shifting task (which 
is part of the computerized CANTAB (Cambridge Neuropsychological Test 
Automated Battery) test)131.The rodent analogue of the ID–ED task is the 
attentional set-shifting task (ASST)132. In this task, rodents learn a series of 
discriminations of increasing difficulty, including the ID–ED discrimination. 
Typically, these discriminations involve associating a particular stimulus 
(for example, odour) with a food reward while simultaneously ignoring 
another stimulus (for example, texture). 
Based on imaging and lesion studies, the ID–ED task has been associated 
with the dorsolateral prefrontal cortex in humans and the medial 
prefrontal cortex in rodents132. Hence the ASST shows functional 
homology with the human task and good construct validity. Although 
widely used in rat models, various methodological considerations — such 
as its low throughput — limit its use in drug discovery.
Working memory
Deficits in working memory are well documented in patients with 
schizophrenia, and it is considered that working memory has some 
executive control component.
The challenges of developing translational working memory tasks in 
rodents have been discussed in the literature133. One concern is that 
current animal models measure what is more akin to short-term memory 
rather than working memory. In addition, in several purported working 
memory tasks rodents are required to hold a single piece of information 
with minimal executive demand (for example, a delayed match to sample 
task). Another important difference is that in humans the prefrontal cortex 
and parietal cortex are involved in spatial working memory tasks, whereas 
in animals these tasks are often dependent on the hippocampus27,134. The 
challenge is to develop rodent models that incorporate executive control 
and the focused recruitment of the prefrontal cortex. One possibility is the 
adaption of the radial arm maze task or other operant tasks in designs that 
model working memory tasks in humans, such as the n-back task134.
Other constructs and the MATRICS cognitive test battery
Other constructs highlighted in the CNTRICS criteria include long-term 
memory, perception and social cognition. Although there is a large amount 
of published literature describing potential animal models of these 
behaviours, they do not accurately reflect the processes that occur in 
humans133. Hence, it is challenging to develop translationally relevant 
animal models of long-term memory, perception and social cognition.
However, numerous cognitive tasks have been developed, including the 
novel object recognition task and other forms of cognitive flexibility, such 
as reversal learning. Although these tasks have been widely applied in 
schizophrenia drug discovery (reviewed in REF. 27), and many studies have 
shown that currently used antipsychotic drugs reverse deficits in these 
tasks (in attempts to validate the task in a particular model), the fact that 
existing antipsychotic drugs have minimal or no efficacy in ameliorating 
cognitive deficits in the clinic suggests that these tasks are generating 
false-positive results and will have limited predictive validity27.
Clinical evaluation
TURNS (Treatment Units for Research on Neurocognition and 
Schizophrenia) is a network of academic sites in the United States that are 
evaluating the potential cognition-enhancing efficacy of identified targets 
in proof-of-concept clinical studies or clinical trials. Initial target selection 
included a7 nicotinic acetylcholine receptor agonists, dopamine D1 
receptor agonists and glutamatergic agents acting at either ionotropic  
or metabotropic receptors. 
Cognitive caveats
Despite recent advances in cognitive neuroscience in relation to 
schizophrenia, the current understanding of the precise neuropsychological 
components (or constructs) and the neural circuitry that underpins these 
components is still evolving. Hence, further adaptations of clinical tests as 
well as tests in animal models will be necessary to ensure valid translation 
across species. In addition, in the drive to mirror human and animal 
constructs of cognition that are relevant to schizophrenia, the following 
points should be considered:
• Rodents are, in many instances, not equipped with the necessary 
neuroanatomical machinery to perform certain human cognitive 
constructs (for example, verbal working memory) 
• The behavioural outcome that is reflected by the recruitment of a 
particular neural system may manifest differently between rodents  
and humans
• The behavioural test may not measure the same animal and human 
construct (for example, working memory)
• The neural circuits for a particular construct may vary between animals 
and humans
• The prefrontal cortex is important in working memory, executive 
function and attention; hence, approaches other than measuring 
behaviour are required to investigate these components 
Overall, there is an appreciation that currently used behavioural assays 
of cognition need to be refined if they are to identify processes that are 
relevant to the cognitive symptoms of schizophrenia and thereby have 
utility in schizophrenia drug discovery.
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Continuous  
performance task 
A task that measures the 
ability of a subject to maintain 
sustained and selective 
attention and inhibitory 
control. 
Radial arm maze 
Usually an eight-armed maze 
that can be used for various 
memory tasks. In the context 
of working memory, a rodent 
explores the eight arms in 
search of food. Working 
memory can be assessed  
by measuring how often the 
animal returns to an arm  
that it has already visited and 
emptied of food reward. 
n-back task 
The subject is presented with a 
series of stimuli and is required 
to respond when the stimulus 
on the current trial matches 
that presented n trials ago.  
The memory load can be 
increased by increasing n.  
The subject has a dual task:  
to encode the current stimulus 
and to compare it with that 
presented on the n-to-last trial. 
Sensorimotor gating
A process of filtering redundant 
or unnecessary stimuli in the 
brain.
Face validity
An animal model or assay  
in which the outward signs 
resemble the human condition 
but may not necessarily be a 
result of the same underlying 
mechanism.
Operant assays
Tasks in which the subject 
learns to behave in such a  
way to obtain rewards or  
avoid punishments.
Parvalbumin 
A calcium-binding protein 
expressed in a subset of GABA 
(γ-aminobutyric acid)-ergic 
cells, including cortical and 
hippocampal basket and 
chandelier cells as well as 
reticular thalamic neurons. 
Levels of parvalbumin in some 
areas of the cortex and 
hippocampus are reduced in 
post-mortem tissue samples 
taken from patients with 
schizophrenia. 
these animals have failed to adequately acquire key com­
ponents of the task and so the results from such studies 
should be interpreted with caution.
The potential of drugs to affect distinct cognitive 
symptoms (or domains) emphasizes the importance of 
assessing novel compounds in a range of behavioural 
assays (as highlighted above). Furthermore, to increase 
the translational relevance of behavioural assays, it will 
be necessary to carry out further optimization of existing 
assays and to develop new behavioural tasks that more 
closely resemble specific subsets of human cognitive 
symptoms that are underpinned by similar circuitry. 
Models based on the GABA hypothesis
There is a close relationship between GABAergic and 
glutamatergic neurons in regions of the brain that are 
involved in schizophrenia. Importantly, the high activ­
ity of NMDA receptors on parvalbumin­containing 
Box 4 | Behavioural assays: positive and negative symptoms
Positive symptoms 
Locomotor activity. The development of current antipsychotic drugs for treating the positive symptoms of schizophrenia 
has been largely influenced by the use of assays based on the dopamine hypothesis. Locomotor activity testing has been 
widely used, because such assays have a relatively high throughput, and because the role of dopamine in the control of 
movement — albeit complex — is well established. The enhanced locomotor response to dopaminergic compounds 
(for example, amphetamine) is associated with altered mesolimbic dopamine transmission and provides a proxy marker 
for detecting positive symptoms64. 
Although the behavioural consequences of increased dopaminergic activity are different in humans and mice, there 
may be shared components of the underlying neurotransmitter mechanisms64. A number of caveats exist: locomotor 
activity is a nonspecific behaviour; the equivalent of locomotor activity in humans is unclear; and compounds could 
reduce locomotor activity by various mechanisms that may not necessarily be related to antipsychotic activity. 
Prepulse inhibition. Prepulse inhibition (PPI) measures sensorimotor gating of the startle reflex and relates to the ability 
of a non-startling pre-stimulus to inhibit the response to a startling stimulus (for example, an auditory or tactile stimulus). 
PPI is disrupted in schizophrenia and may relate to pre-attentional filtering, which is a precognitive process that prevents 
sensory overload and cognitive fragmentation (reviewed in REF. 126). As PPI is a cross-species phenomenon, it offers 
some face validity as a behavioural assay. Although reversal of PPI deficits induced by amphetamine and/or apomorphine 
is often used as a predictive assay for antipsychotic activity in preclinical rodent models, the exact relationship between 
PPI and specific symptoms in schizophrenia remains to be clarified27. There are also differences in the responses observed 
between rats and mice, and even between different strains of mice, in terms of baseline responses and responsiveness to 
antipsychotic drugs. 
In addition to schizophrenia, PPI deficits are observed in various other neuropsychiatric diseases including Huntington’s 
disease, bipolar disorder and obsessive compulsive disorder. Perhaps this is not surprising, given that the neural circuitry 
that underpins PPI involves diverse neural systems encompassing the brainstem and peduncolopontine as well as 
hippocampal, amygdaloid and prefrontal cortical regions63.
In summary, reversal of dopamine-mediated hyperlocomotor activity and PPI deficits offers some predictive validity in 
the identification of antipsychotic compounds as treatments for the positive symptoms of schizophrenia. In addition, 
despite their limitations, these assays are used to assess schizophrenia-like behaviours in other models (for example, 
NMDA (N-methyl-d-aspartate) receptor antagonist models and genetic models) for the purposes of drug discovery. 
Negative symptoms
The development of assays that reflect the negative symptoms of schizophrenia in rodent models represents a 
considerable challenge. Clearly, some of these symptoms are uniquely observed in humans and are not readily accessible 
in animal models. Furthermore, the clinical heterogeneity of negative symptoms and the limited understanding of the 
underpinning neurobiology confounds the development of translationally relevant assays. Nevertheless, various assays 
have been developed127, including measurements of social behaviours, anhedonia, blunted affect (emotional expression) 
and avolition. Most studies have examined social behaviours but it is currently unclear how these behaviours correspond 
to human behaviours, and anxiety-induced confounding factors are implicit in these tests. Similarly, reduced emotional 
expression has been examined in anxiety tests such as the elevated plus maze test, but the extent to which these tests 
represent anxiety disorders in humans is unsubstantiated. 
Anhedonia is typically measured using a sucrose preference test and shows sensitivity to antidepressant drugs. 
However, given that avolition rather than anhedonia is now considered to be an important feature of the negative 
symptoms of schizophrenia119, the sucrose preference test is unlikely to represent a useful assay. The same argument can 
be applied to other tests that assess behavioural despair (such as the forced swim test and the tail suspension test) and 
are also sensitive to antidepressant drugs.
Avolition is arguably the component of negative symptoms that is most relevant to the disease, and there is a 
substantial amount of literature on the neurobiological mechanisms underpinning motivation in preclinical settings128. 
Operant assays that measure motivation include progressive ratio tasks, in which animals work to obtain a food reward. 
Animals are required to press a lever or poke their nose into an aperture an increasing number of times over successive 
trials to obtain a food reward. The ‘breakpoint’ is defined as the first criterion level that the animal is unable to complete, 
and provides an index of avolition. The translational potential of these tests (which may be considerable) has yet to be 
fully exploited.
In summary, until there is a better understanding of the neurobiological mechanisms underlying the negative symptoms 
of schizophrenia, there can be no certainty regarding the predictability of preclinical assays for drug discovery. To date, 
the assays that hold most promise are the operant-based motivational tasks.
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γ-oscillations 
Oscillatory waves detected in 
human electroencephalogra-
phy, with a frequency typically 
around 40 Hz; thought to be 
related to consciousness.
Basket cells 
A class of GABA 
(γ-aminobutyric acid)-ergic 
inhibitory interneurons that 
innervate the perisomatic 
region of target neurons.  
The axonal arborization of 
basket cells often resembles  
a basket surrounding the 
target cell body. 
Chandelier cells 
A class of GABA 
(γ-aminobutyric acid)-ergic 
interneurons of the cerebral 
cortex that ensheathe the axon 
initial segment of up to 200 
pyramidal cells with cartridge 
synapses to directly control 
action potential generation. 
Working memory 
The active maintenance of 
limited amounts of information 
for a short period of time to 
guide thought processes or 
sequences of behaviour.  
High penetrance
A genetic mutation that has a 
substantial influence on the 
risk of disease.
Deep re-sequencing 
A technique, typically 
performed using high- 
throughput next-generation 
sequencing, used to obtain the 
complete nucleotide sequence 
of a gene or genome that has 
previously been determined. 
The term ‘deep’ refers to the 
depth, coverage or the number 
of times an individual 
nucleotide is sequenced.
Global mining 
Non-hypothesis-driven 
screening of an entire set of 
biological material, such as the 
use of microarrays to screen  
all the RNA from a particular 
cell type. 
GABAergic interneurons highlights the fact that block­
ing NMDA receptor activity will have an impact on 
GABAergic transmission39. This is proposed to be par­
ticularly important during the vulnerable developmental 
period40. It is therefore not surprising that key deficits 
in GABAergic pathology have been demonstrated in 
schizophrenia. Importantly, parvalbumin­containing 
GABAergic interneurons are important in the genera­
tion of γ-oscillations, which are important in cognition 
and disrupted in schizophrenia.
Post­mortem studies on central nervous system tissue 
have revealed that markers of particular subpopulations 
of GABAergic interneurons — namely parvalbumin­
containing basket cells and chandelier cells (axo­axonic 
cells) — are decreased in the prefrontal cortex and 
temporal cortex of patients with schizophrenia41,42. 
Parvalbumin is expressed at a relatively late stage during 
development, and because it contributes to neuroprotec­
tion the basket and chandelier cells may be vulnerable to 
perinatal ischaemic episodes. Hence, a primary role for 
GABAergic interneuron dysfunction in the aetiology of 
schizophrenia is in line with the known developmental 
risk factors of the disease43,44. 
Furthermore, there is mounting genetic and molecu­
lar evidence for the altered expression of GABA type A 
(GABAA) receptor subunits and GABA signalling in 
schizophrenia45,46. Although there is strong evidence 
that deficits in GABAergic neurons are present in patients 
with schizophrenia, only specific subpopulations of 
GABAergic interneurons are likely to be involved, and 
selectively targeting these pharmacologically is challeng­
ing. GABAA receptor subtypes that are specific to these 
interneurons have not yet been identified, but a GABAA 
α2­ and α3­subtype­selective modulator had modest 
cognition­enhancing effects in a small group of patients 
with schizophrenia47. Based on the robust evidence for 
cortical GABAergic dysfunction in schizophrenia, pre­
clinical models have focused on modifying GABAergic 
transmission indirectly (using NMDA receptor antago­
nists) rather than directly (using drugs that act on GABA 
receptors). Future strategies for drug discovery could 
focus on restoring the dysfunction in GABA­mediated 
disturbances in γ­oscillations, which may underpin the 
cognitive deficits observed in schizophrenia.  
Neurodevelopmental models
Antenatal and perinatal environmental factors substan­
tially increase the risk of developing schizophrenia; of 
these, prenatal infection or malnutrition and obstetric 
complications are among the most established risk fac­
tors48. This knowledge has stimulated the development of 
models based on direct prenatal and/or perinatal damage 
to the central nervous system. The rat neonatal ventral 
hippocampal lesion model is used to study the conse­
quences of early damage to the hippocampus49. Although 
the construct validity of this model is lower than the con­
struct validity of some other models, some neurochemical 
and behavioural changes are observed that can be linked 
to schizophrenia50–52, and PPI deficits are ameliorated 
by the administration of atypical anti psychotic drugs 
in this model52. 
In a related approach, rats exposed to the toxin methyl­
azoxymethanol (MAM) in utero at embryonic day 17 
(E17) exhibit impaired cortical development and a loss 
of parvalbumin­containing interneurons, in addition to 
deficits in working memory, set­shifting and PPI in adult­
hood53. There is little information available at present 
as to how sensitive these MAM­induced changes are to 
antipsychotic drugs. 
Rearing of rats in isolation has also been used to model 
aspects of schizophrenia, as this affects the development 
of various regions of the brain (such as the prefrontal 
cortex) and leads to lasting PPI deficits54; however, it is 
worth remembering that childhood trauma is not a major 
risk factor for this disease48. Maternal administration of 
the viral mimetic polyinosinic:polycytidylic acid (polyI:C) 
at E15–E17 reportedly produces a spectrum of neuro­
chemical and behavioural changes in the offspring that 
can be related to schizophrenia55. Some of these changes 
are sensitive to antipsychotics56.
Overall, it is likely that the greatest utility of neuro­
developmental models — such as maternal polyI:C admin­
istration — may be observed in combination with genetic 
models, as this would allow the genetic–environmental 
interactions that are central to the aetiology of schizo­
phrenia to be captured in a single paradigm. 
Genetic models 
A plethora of genetic rodent models are being developed, 
which we discuss below, but it is unrealistic to replicate 
the complex genetic architecture of schizophrenia in a 
single rodent model.
Genetic architecture of schizophrenia
Schizophrenia is a polygenic disorder that can be sporadic 
as well as familial. Many epidemiological studies have 
shown that genetic factors account for approximately 
60–80% of the variance in overall risk57. As well as the addi­
tive effects of gene networks, interactions between genetic 
and environmental risk factors have an important role1.
The genetic architecture of schizophrenia is complex 
and it is likely that a combination of genetic variants con­
tribute to the risk, including common single nucleotide 
polymorphism (SNP) alleles that have a small effect, as 
well as rare coding mutations and copy number variant 
alleles that have a high penetrance58. Estimates suggest that 
more than 1,000 genes are likely to be involved in the 
aetiology of schizophrenia59. Deep re-sequencing — cur­
rently using targeted approaches — of candidate genes, 
exomes and chromosomal regions, and very­large­scale 
genome­wide association studies are underway to inves­
tigate the many remaining questions surrounding the 
genetic architecture of schizophrenia.
Ultimately, animal models are needed to address the 
genetic architecture of the disorder, taking into account 
both common and rare variants as well as the combina­
tion of alleles required to cause the disease, along with 
the molecular consequences, identified by global mining 
of the transcriptome and proteome. Clearly, the pro­
found heterogeneity in schizophrenia raises major chal­
lenges for modelling the disease in animals. Similarly, it is 
important to consider interactions between genetic and 
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22q11 syntenic region 
Synteny describes the 
preservation of colocalized 
genes on chromosomes in 
different species. Mouse genes 
that are orthologous to the 
human genes that map onto 
human chromosome 22q11 
are grouped together on 
mouse chromosome 16.
Progressive ratio schedule 
A schedule in which the 
number of responses a subject 
is required to make to obtain a 
reinforcement (such as a food 
reward) increases progressively. 
A typical performance 
measures the ratio at which 
responding ceases for a 
predefined period, which may 
be related to the subject’s 
motivational state. 
environmental factors. Such studies are underway and 
hold promise60; characterizing the complexity of these 
genetic–environmental interactions to determine the 
likelihood of developing schizophrenia may be central 
for establishing translationally valid preclinical models of 
schizophrenia. In addition, it is vital to use genetic ani­
mal models that closely replicate the characteristics of the 
human genetic variants that contribute to an increased 
risk of developing schizophrenia, as this would ensure 
maximal translational validity. Furthermore, understand­
ing the impact of genetic manipulation on neurobiological 
pathways is crucial for identifying novel targets.
Phenotyping of genetically modified mice 
Many genetically modified mice have been developed 
that target candidate genes (well­characterized and emer­
gent candidate genes) and established pathophysiological 
mechanisms (for example, glutamatergic and dopaminer­
gic processes). Such mice are providing valuable insight 
into the neurobiological role of specific genes and neuro­
transmitters in terms of behavioural phenotypes, as well 
as the impact of these specific genes and neurotransmitters 
on downstream biochemical pathways, synaptic func­
tion, structural and neuropathological alterations as well 
as neurodevelopmental processes. Importantly, several 
candidate genes affect neurotransmitter systems that are 
considered to be disrupted in schizophrenia (FIG. 1). This 
convergence adds weight to the utilization of genetically 
modified mice for translational studies.
It could be argued that studies in genetically modified 
mice that have rare variants of high penetrance, such as 
disrupted in schizophrenia 1 (DISC1) and the 22q11.2 
syntenic region, will hold the most promise for inform­
ing on disease mechanisms and hence have utility in 
drug discovery. However, it is important to remember 
that schizophrenia is a complex heterogeneous disease 
and that multiple genes and pathways affect the neural 
circuitry that underlies the distinct and overlapping symp­
toms. Commonalities between phenotypes in different 
genetically manipulated mouse strains may thus be highly 
informative, as has been previously argued61. Therefore, 
information gained from a range of genetically modified 
mice, and from other genetic and functional studies, will 
prove to be valuable in assembling the true neurobiologi­
cal mechanisms of the disease. 
The results of behavioural phenotyping from various 
genetically modified mice are summarized in TABLE 2. 
Our criteria for selection was to incorporate genetically 
modified mice that fall into one of the following three 
categories: mice expressing modified key candidate 
genes, based on consistent genetic and molecular evi­
dence (using information from the SchizophreniaGene 
database meta­analyses)62; mouse models based on 
pathophysiological evidence; and mouse models based 
on strong systems­led evidence (for example, where 
a protein encoded by a particular gene is known to 
affect a biochemical and/or neural pathway that has 
an established role in the disease). It is notable that the 
phenotypic characterization of genetically modified 
mice has typically been conducted using assays such as 
PPI and locomotor activity, and few studies have used 
translationally relevant assays for studying cognitive 
deficits and negative symptoms (TABLE 2). It is clear that 
PPI and hyperlocomotor activity are not measures of 
positive symptoms per se, yet they have been widely used 
as predictive screens for antipsychotic compounds.
Numerous genetically modified mice, including 
those with disruptions in Disc1, neuregulin 1 (Nrg1) and 
glutamate­related genes, show altered locomotor activ­
ity and deficits in PPI (TABLE 2). Authors often interpret 
this as a demonstration of schizophrenia­like behaviours. 
This explanation is an oversimplification, and a more 
precise interpretation would be that the genetic altera­
tion modifies the neurobiological mechanisms underpin­
ning these behaviours. Given the diversity of the neural 
systems recruited in PPI63, it is perhaps not surprising 
that the disruption of these systems by numerous strate­
gies and genetic alterations can result in PPI deficits. This 
raises questions about the utility of these phenotypes for 
drug discovery. Nevertheless, assessing such phenotypes 
in genetic models does move away from the problems of 
so­called ‘receptor tautology’, which is inherent to models 
in which a dopamine receptor agonist produces behav­
ioural disruptions that are — not surprisingly — restored 
by dopamine receptor antagonists.
Interestingly, mice with genetic modifications in the 
dopamine receptor display no overt PPI deficits and 
no consistent change in a locomotor activity pheno­
type (TABLE 2). It is possible that compensatory changes, 
including changes in the expression of other receptors, 
may mask the expression of a behavioural phenotype. 
Importantly, clear phenotypes can be revealed following 
pharmacological challenges, thus providing important 
mechanistic insight64. Hence, a lack of an overt phenotype 
may not rule out the involvement of a particular gene in 
regulating a behaviour.
Taken together, this evidence suggests that assays 
of hyperlocomotor activity and PPI have questionable 
value in future drug discovery strategies. 
Phenotypic assessment of negative symptoms. Few stud­
ies have examined negative symptom­like behaviours in 
mutant models. Anhedonia­like symptoms have been 
reported in a Disc1­modified mouse line (Q31L), as 
assessed by the forced swim test and sucrose preference 
test. However, behaviours relating to motivation are likely 
to be more relevant to the negative symptoms of schizo­
phrenia. In this regard, Kellendock65 showed that mice 
overexpressing D2 receptors in the striatum exhibited 
reductions in lever pressing for food reward in a progres-
sive ratio schedule, which is consistent with impairments 
in motivation (TABLE 2).
Phenotypic assessment of cognitive symptoms. Many 
of the genes that are studied in schizophrenia, includ­
ing DISC1, NRG1 and dystrobrevin binding protein 1 
(DTNBP1), are present in brain circuitry that is important 
in cognition, and the proteins encoded by these genes are 
often functionally linked to glutamatergic synapses (FIG. 1). 
Given that glutamatergic neurotransmission is fundamen­
tal to synaptic plasticity and cognition, it is evident that 
schizophrenia­related genes are likely to affect cognitive 
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processes. Understanding how the disruption of specific 
genes affects discrete cognitive processes is paramount for 
the success of future drug discovery strategies. 
Although assays for cognitive testing in genetically 
modified mice require further optimization to increase 
their translational relevance, there are some tasks that are 
homologous to human constructs and that recruit prefron­
tal circuitry; these include the ASST and the 5­CSRTT. 
As such, they provide a good starting point for cogni­
tive phenotyping in genetically modified mice and have 
great potential in drug discovery. To date, however, there 
are only isolated studies in which genetically modified 
mice have been assessed in cognitive tasks. Instead, rather 
broad behavioural phenotypes have been assessed, which 
have methodological confounds and are subject to inter­
pretational caveats (TABLE 2).
Nevertheless, the role of glutamate receptor subtypes 
is being investigated in a rigorous manner. For example, 
Bannerman’s group66,67 report that knockout mice deficient 
in AMPA (α­amino­3­hydroxy­5­methyl­4­isoxazole pro­
pionic acid) receptor 1 (GluR1 (also known as GluA1); 
Gria1–/– mice) and in the NMDA receptor (NR2A (also 
known as GluN2A); Grin2a–/– mice) display hippocampal­
dependent deficits in working memory but not in refer-
ence memory. Furthermore, region­specific, inducible and 
reversible knockout mice with altered expression of the 
NR1 subunit of the NMDA receptor (NR1 (also known 
as GluN1); Grin1–/– mice) have also been constructed. 
Findings from these mice are beginning to reveal the 
regional and temporal contributions of NMDA receptors 
in constructs of cognition more precisely68.
It should also be recognized that cognitive deficits 
are common to many neurological and psychiatric dis­
orders; however, it is not known whether these defects 
result from the same disrupted neurobiological mecha­
nisms and brain circuitry. Hence, the impact of genetic 
manipulation on behaviour alone will not necessarily 
be sufficient to understand whether convergent and 
divergent mechanisms exist across a range of neuropsy­
chiatric and neurological disorders. Other approaches, 
incorporating functional brain imaging and electrophys­
iology, should shed light on the distinct process involved.
Finally, it should be highlighted that a plethora of 
data have been published that have minimal transla­
tional relevance owing to the confounding factors asso­
ciated with rodent behavioural assays (for example, the 
fact that the cognitive task may not measure the same 
human construct, or that a cognitive task can be sensi­
tive to interference by effects such as low motivation 
or sedation; BOX 3) as well as factors associated with 
the use of genetically modified mice themselves (for 
example, the background strain; BOX 5). Often, it has 
been claimed that genetically modified mice exhibit a 
schizophrenia­like behavioural phenotype, yet the evi­
dence presented is subject to confounding factors that 
cloud this interpretation (BOX 5).
Drug evaluation in genetic mouse models 
Despite the availability of a considerable amount of data 
on the behavioural phenotyping of mouse models of 
risk genes for schizophrenia (TABLE 2), there are limited 
Figure 1 | Genes implicated in schizophrenia converging at the synapse and 
nucleus. The schematic representation shows the functional relationship between 
some of the most prominent genes that are implicated in the aetiology of 
schizophrenia. Many of these genes are involved in glutamate synapse function.  
In particular, disrupted in schizophrenia 1 (DISC1) forms a complex with 
phosphodiesterase 4B (PDE4B) and TNIK (TRAF2 and NCK-interacting kinase)  
to coordinate signalling pathways that regulate synaptic structure and gene 
transcription. Similarly, neuregulin 1 (NRG1)–ERBB4 signalling regulates synapse 
morphology and function. The α7 subunit-containing nicotinic acetylcholine 
receptors (nAChRs), which are strongly implicated in disease risk via gene copy 
number variations, are located on presynaptic glutamatergic terminals. Major 
histocompatibility complex (MHC) molecules have some role in the maintenance  
and plasticity of synaptic connections, but this is currently not well characterized.  
At the nucleus, a proteolytic product of Notch 4 is a transcriptional regulator, as are 
transcription factor 4 (TCF4) and zinc finger protein 804A (ZNF804A). The perinuclear 
centrosome acts as a microtubule-organizing centre and has a well-established role  
in mitosis. Its function in post-mitotic neurons remains unclear but it has been 
proposed to have a role during neuronal development and migration. Pericentriolar 
material 1 (PCM1) sequence variations may represent one of the greatest genetic 
influences currently reported on the risk of developing schizophrenia. Genes have 
been selected based on information from the Schizophrenia Gene database 
meta-analyses62; DISC1 interactions have been covered in detail in REF. 136.  
AMPAR, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor; 
mGluR, metabotropic glutamate receptor; NMDAR, NMDA (N-methyl-d-aspartate) 
receptor; PRSS16, serine protease 16; VGLUT1, vesicular glutamate transporter 1.
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examples of pharmacological studies in the most inves­
tigated candidate gene models (TABLE 3). 
Notably, the most widely assessed behavioural pheno­
types are PPI and locomotor activity. Notwithstanding 
the limitations of these tasks, examination of two Disc1­
mutant mouse models has revealed differences in sen­
sitivity to antipsychotic drugs during the rescue of PPI 
deficits. Clozapine and haloperidol partially reversed a 
Table 2 | Behavioural phenotyping of genetically modified mice*
Mouse model  
(genetic modification) 
Novelty-
induced  
LMA
PPI Anhedonia and 
avolition tests
Sociability, social 
novelty and  
social interaction
Spatial working 
and short-term 
memory
Refs
Candidate gene-related: DISC1 
Q31L homozygotes  
(amino acid substitution) 
✕ Ambiguity‡ Ambiguity‡ in FST 
✓ in SPT;  
ND in other study
Ambiguity‡ Ambiguity‡ in 
DNMP
69,72
L100P homozygotes  
(amino acid substitution) 
Ambiguity‡ Ambiguity‡ ✕ in FST 
✕ in SPT;  
ND in other study
✕ (in both studies) Ambiguity‡ in 
DNMP
69,72
Disc1-truncated hemizygotes  
and homozygotes
✕ ✕ ND ND ✓ in DNMP 137,138
Dominant negative Disc1- 
truncated hemizygotes
✕ ND ✓ in TST ND ND 73
Dominant negative Disc1- 
truncated hemizygotes  
(truncated carboxy-terminal  
with CaMKIIα promoter) 
✓ ✓ ✓ in FST ✕ ✕ in SA 139
In utero Disc1 shRNA knockdown ✕ ✓ ✕ in FST ND ✓ in DNMP 140
Disc1-truncated  
(inducible promoter)  
✕ (✓ in 
males only)
✕ ✕ in FST  
(✓ in females only) 
✕ in TST
✕ (✓ in males only) ✕ in SA 141,142
Disc1-truncated (transient  
expression induced on postnatal 
day 7; inducible promoter)
ND ND ✓ in FST ✓ ✓ in DNMP 143
Disc1 knockout mice  
(Disc1Δ2–3/Δ2–3 mice)‡ 
✕ ✓ ✕ in FST ✕ (sociability 
increased)
✕ in SA 
✕ in RAM
144
Candidate gene-related: NRG1
Nrg1+/– knockout mice ✓ ✓ ND ND ND 145
Nrg1+/– type III knockout mice  
(CRD isoform)
✕ ✓ ND ND ✓ in DNMP 146
Nrg1+/– type I, II and III knockout  
mice (transmembrane domain)
ND ND ND ✓ ✕ in SA 147
Gandidate gene related: ERBB4 (neuregulin receptor); DISC1-related; chromosome 22q11.2
Erbb4+/– knockout mice ✓ ✕ ND ND ND 145
Erbb4+/– and Erbb4–/–  
knockout mice
✕ (LMA 
reduced)
ND ND ND ND 148
Erbb2/b4–/– CNS knockout  
mice
✕ ✓ ND ND ND 149
PV-Cre; Erbb4−/− knockout mice ✓ ✓ ND ND ✓ in RAM 77
Pde4b–/– knockout mice  
(Disc1 interactor) 
✕ (LMA 
reduced)
✓ ✓ in FST ND ND 150
Pafah1b1+/– knockout mice  
(Disc1 interactor) 
✕ ✕ ND ND ND 151
Human chromosome 22q11.2  
sytenic deletion (Df (16)A+/– mice)§
ND ND ND ND ✓ in DNMP 105
Human chromosome 22q11.2  
sytenic deletion (Lgdel+/– mice)§ 
✕ ✓ ND ND ND 152
Human chromosome 22q11.2  
syntenic deletion (Df1+/–  mice)§
✕ ✓ ND ND ND 153
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Human constructs 
In relation to cognition,  
human constructs are specific 
elements of mental processes, 
such as attention, memory, 
producing and understanding 
language, solving problems  
and making decisions.
Reference memory 
Also known as long-term 
memory. In rodents this 
typically involves reference to 
external cues, which is needed 
for succesful completion of 
tasks such as finding a hidden 
platform in the Morris water 
maze. 
severe PPI deficit and increased locomotor activity in 
Disc1­mutant mice with the L100P mutation but had no 
effect on a weaker PPI deficit in Disc1 mutants with the 
Q31L mutation. In the forced swim test, Disc1 mutants 
with the Q31L mutation exhibited a ‘depressed’ pheno­
type that was reversed by the monoaminergic drug 
bupropion, whereas Disc1 mice with the L100P mutation 
did not exhibit deficits in this test. These findings led the 
authors to conclude that Disc1 missense mutations can 
lead to distinct phenotypes that are related to depres­
sion and schizophrenia, and that these phenotypes 
are dependent on the localization of the alterations in 
the Disc1 gene. Further pharmacological probing with 
inhibitors of phosphodiesterase 4B and glycogen syn­
thase kinase suggested that the expression of a range of 
schizophrenia­like behaviours involves the interaction 
of DISC1 with phosphodiesterase 4B and glycogen syn­
thase kinase69,70. 
However, recent studies — in which minimal behav­
ioural phenotypes have been observed — question the 
validity of these findings71,72. Mounting evidence suggests 
that the observed phenotypes could potentially have been 
the result of inadequate backcrossing of the mice, and 
thus the phenotypes could have been influenced by the 
genetic background instead of being attributable to 
the Disc1 missense mutation per se. Furthermore, the 
direct translational relevance of the genetic mutation pre­
sent in these animals to the mutation present in patients 
with schizophrenia (the DISC1 mutation; a T1q43;11q21 
translocation) is arguably weaker than that of more 
Table 2 (cont.) | Behavioural phenotyping of genetically modified mice*
Mouse model  
(genetic modification) 
Novelty-
induced 
LMA
PPI Anhedonia 
and avolition 
tests
Sociability, social 
novelty and social 
interaction
Spatial working  
and short-term 
memory
Refs
Dopamine-related 
Drd1a–/– knockout mice ✕ ND ND ND ND 154
Drd1–/– knockout mice ✓ ND ND ND ND 155
Drd2–/– knockout mice ✕ (LMA 
reduced)
 ✕ (PPI 
reduced)
ND ND ND 156,157
Drd2-transgenic mice  
(inducible Drd2 overepxression)
✕ ✕ ✓ in ProgR ND ✓ in RAM 
✓ in DNMP
65,158
Comt–/– and Comt +/– knockout mice ✕ ✕ ND ✕ ✓ in SA 159,160
 Slc6a3–/– knockout mice (DAT) ✓ ✓ ND ✓ ✕ in MWM|| 
✓ (impaired adaption)
75,161, 
162
Glutamate-related 
Grin1–/– knockdown mice (NR1) ✓ ✓ ND ✓ ND 163,164
Grin2–/– knockout mice (NR2A) ✓ ✕ ✕ in FST ND ✓ in RAM 
✓ in DNMP 
✕ in MWM||
67,165, 
166
Gria1–/–  knockout mice (GluR1) ✓ ✓ ✕ in SPT ✓ ✓ in RAM 167–169
Gria4–/–  knockout mice (GluR4) ✕ ✓ ND  ✕ ✕ in DNMP 170
Ppp1r2-cre+/–/NR1loxP/loxP  ablation of NR1  
receptors in GABA interneurons
✓ ✓ ✓ in SPT ✓ ✓ in SA 171
Slc17a7+/–  knockout mice (VGLUT1) ✕ ND ✓ in FST 
✓ in SPT
ND ND 172,173
Akt1–/–  knockout mice ✕ ✓ ✓ in TST ND ✕ in SA 174,175
Dtnbp1–/–  knockout mice ✓ ✕ (PPI 
enhanced) 
ND ND ✓ in DNMP (operant 
chamber and T maze)
176–179
✓, disease-relevant phenotype detected; ✕, no disease-relevant phenotype detected; +/–, heterozygote for gene disruption; –/–, homozygote for gene disruption; 
CaMKIIα, calcium/calmodulin-dependent protein kinase IIα; CNS, central nervous system; COMT, catechol-O-methyltransferase; CRD, cysteine-rich domain 
(present in some NRG1 isoforms); DISC1, disrupted in schizophrenia 1; DNMP, delayed non-match to place test (T maze); DRD1A, dopamine receptor D1A; FST, 
forced swim test; GABA, γ-aminobutyric acid; GRIA1, AMPA-selective glutamate receptor 1; GRIN1, NMDA receptor subunit NR1; LMA, locomotor activity; MWM, 
Morris water maze task; ND, not determined; NMDA, N-methyl-d-aspartate; NRG1, neuregulin 1; PAFAH1B1, platelet-activating factor acetylhydrolase 1b 
regulatory subunit 1; PDE4B, phosphodiesterase 4B; PPI, prepulse inhibition; PPP1R2, protein phosphatase inhibitor 2; ProgR, progressive ratio schedule; PV-Cre, 
mice expressing Cre recombinase under the control of the parvalbumin gene promoter RAM, radial arm maze; SA, spontaneous alternation (T maze); shRNA, short 
hairpin RNA; SLC6A3, solute carrier 6 member 3 (also known as DAT; dopamine transporter); SPT, sucrose preference test; TST, tail suspension test; VGLUT1, 
vesicular glutamate transporter 1 (also known as SCL17A7). *Of the strains shown, genetically modified Disc1 mice are among the few to be evaluated for latent 
inhibition; the point mutants and the mutant mice expressing a carboxy-terminal truncated form of Disc1 under the CaMKIIα promoter showed schizophrenia-
related deficits in this task69. Drd2-overexpressing mice appear to be the only strain tested for executive function (attentional set-shifting and reversal learning); 
the mutants showed mild deficits in reversal trials but not in schizophrenia-related extradimensional–intradimensional deficits in this task. Approaches in which 
region-specific deletions in genetically modified mice are utilized are generally not shown here. For example, deletion of NR1 subunits in subregions of the 
hippocampus revealed regionally specific roles in spatial memory tasks68, and NR1 subunit ablation on parvalbumin-positive interneurons impaired working 
memory in the T maze task180. ‡‘Ambiguity’ refers to evidence both for and against a disease-relevant phenotype.  §Disc1Δ2–3/Δ2–3 mice are Disc1-mutant mice lacking 
exons 2 and 3 of the Disc1 gene owing to a targeted disruption of Disc1 exons 2 and 3. Df(16)A+/– , Lgdel+/– and Df1+/– mice are mutant mice with deletions of mouse 
chromosome 16, which models a microdeletion on human chromosome 22q11.2 in velocardiofacial syndrome, DiGeorge syndrome and 22q11 deletion syndrome 
developmental disorders (‘Lgdel’ refers to a larger deletion). ||For the MWM, results are presented for working memory but not reference memory paradigms. 
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recently developed genetically modified Disc1 models73. 
Exactly how a risk mutation is modelled is also crucial. 
Indeed, opposing effects of Disc1 manipulation on neu­
ronal growth and maturation have been observed46,74, 
raising questions about which targets are most appropri­
ate in drug discovery.
Antipsychotic drugs have varying abilities to reverse 
PPI deficits in genetically modified mice in which the 
region sytenic to human chromosome 22q11 is dis­
rupted, or mice in which Nrg1, Erbb4 (also known as 
Her4), Akt1 or genes encoding NMDA receptors have 
been disrupted (TABLE 3). Interestingly, this is in stark 
contrast to the clear rescue of PPI and locomotor hyper­
activity by various antipsychotic drugs in dopamine 
transporter (DAT; also known as SLC6A3) knockout 
mice75,76. This may be reconciled by the fact that DAT 
knockout mice exhibit marked dopaminergic dysregula­
tion, which is likely to be rescued by antipsychotic drugs 
acting via D2 receptors. It is probable that the genetic 
alterations in ‘schizophrenia­related genetically modi­
fied mice’ do not disrupt the dopaminergic system to 
the same degree, and other neurobiological pathways 
are affected. Alternatively, variations in the background 
strain and testing conditions may account for these 
differences. 
The extent to which pharmacological agents rescue a 
given behavioural phenotype in a mouse model may also 
be confounded by other nonspecific effects of the drugs. 
For example, clozapine has a sedative effect at doses in 
excess of 1 mg per kg, and this may explain the putative 
reversal of hyperlocomotion rather than a specific rever­
sal of gene­induced hyperlocomotion. Similarly, without 
an interaction between the drug and the genotype in 
the analysis, it is difficult to conclude whether a drug 
is reversing a distinct phenotype, and the finding that a 
drug reduces schizophrenia­like behaviour to a similar 
degree in both mutated and wild­type mice should be 
interpreted with caution.
Pharmacological agents have been used to probe the 
neurotransmitter systems involved in a phenotype. For 
example, Wen et al.77 demonstrated that the GABAergic 
positive allosteric modulator diazepam rescued PPI 
deficits in mice in which Erbb4 had been ablated in 
parvalbumin­positive GABAergic interneurons. This, 
along with neurochemical and electrophysiological evi­
dence, provided greater insight into the role of NRG1 
in neural transmission. These approaches are therefore 
necessary to provide mechanistic insights into the role 
of neurotransmitter systems in models with particular 
genetic manipulations.
In summary, there have been limited drug discovery 
studies using genetically modified mouse models, and 
most studies have focused on using assays that have 
questionable translational relevance. Although some 
proof­of­concept studies have been conducted using 
existing antipsychotic drugs (for example, clozapine and 
haloperidol) in mutated mice exhibiting deficits in PPI 
and locomotor activity, there are a dearth of studies inves­
tigating compound rescue in genetically modified mice 
exhibiting negative symptoms and cognitive deficits. 
Nevertheless, a recent study demonstrated that a 5­HT2C 
receptor antagonist, but not haloperidol (as predicted), 
increased motivation in mice in which the D2 receptor 
is overexpressed — these mice are reluctant to work for 
rewards78. This study is encouraging as it suggests that 
drug­induced rescue is possible in a behavioural assay 
that has translational relevance to the negative symptoms 
of schizophrenia. 
Assessing compound­induced rescue in genetically 
modified mice that exhibit translationally relevant schizo­
phrenia­like behaviours provides a major opportunity for 
future drug discovery. However, harmonization of behav­
ioural phenotyping strategies across laboratories is crucial. 
Furthermore, rigorous pharmacological analysis of test 
compounds in clearly defined genetic phenotypes is nec­
essary to obtain results that can be met with confidence.
Box 5 | Interpreting data from genetic mouse models: confounding factors 
The main confounding factors in the interpretation of findings from genetic mouse models are the effects of  
the background strain, neurodevelopment and interactions between genetic and environmental factors. Some 
background strains have altered levels of emotionality and a different cognitive profile compared to other strains135. 
Hence, the role of the mutation or genetic variation under investigation may be masked by the effects of the 
background strain. Altering a gene (for example, by knocking it out) throughout the developmental period may result 
in the induction of compensatory processes that in turn may cloud the effects of the mutation under investigation. 
Furthermore, housing conditions and stress responses (either through the housing environment or the behavioural 
test itself) may interact with the gene of interest, resulting in a phenotype reflecting a genetic–environmental 
interaction rather than simply a single-gene mutation. Clearly, these ‘gene–environment’ phenotypes are of 
considerable importance from a disease perspective but it is important to understand the mechanisms underlying 
genetic–environmental interactions from a neurobiological perspective.
Interpretation of data generated from behavioural tasks also necessitates careful consideration of potential 
confounding factors. These are often not given the attention they deserve. Teasing out the relevant component  
from the many factors that can affect a behavioural output requires several approaches, many of which cannot be 
measured in a single test. For example, deficits in executive control can affect attention, long-term memory and 
working memory. Similarly, an inability to encode associations between a stimulus and a reward may affect an animal’s 
ability to perform goal-directed behaviours. Hence, an apparent anhedonic phenotype may in fact be due to aberrant 
encoding of information. Clearly, sensory impairments may also affect a range of behavioural outcomes. For example, 
potential confounding factors such as hearing loss and startle reactivity are important considerations in the evaluation 
of a prepulse inhibition phenotype. 
L100P mutation 
A genetic modification induced 
by N-ethyl N-nitrosourea 
mutagenesis in the mouse 
disrupted in schizophrenia 1 
(Disc1) gene, whereby an 
adenine to thymine nucleotide 
transition causes the amino 
acid at position 100 of the 
DISC1 peptide to change  
from a leucine to a proline.
Q31L mutation
A genetic modification induced 
by N-ethyl N-nitrosourea 
mutagenesis in the mouse 
disrupted in schizophrenia 1 
(Disc1) gene, whereby a 
thymine to cytosine nucleotide 
transition causes the amino 
acid at position 31 of the 
DISC1 peptide to change from 
a glutamine to a leucine.
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Intermediate phenotypes 
A promising approach for drug discovery is to assess 
compounds in translational behavioural assays in ani­
mal models that have improved construct validity. The 
recent development of genetic mouse models, along with 
improved behavioural methods for assessing disease­
related phenotypes, is encouraging from this perspective. 
In particular, the identification of rare genetic variants that 
dramatically increase the risk of developing schizophre­
nia will facilitate the development of rodent models with 
high construct validity. There are however, some impor­
tant gaps that need to be filled if we are to overcome the 
current translational bottleneck.
It is imperative to gain knowledge of the neural cir­
cuitry and neurophysiological mechanisms underpinning 
the symptoms of schizophrenia, and how genetic varia­
tion affects neural systems to predispose individuals to 
specific disease symptoms. These so­called intermediate 
phenotype­ (or endophenotype)­based approaches are 
capturing much attention79,80. In essence, intermediate 
phenotypes can be viewed as measurable components 
along the pathway between a defined risk factor (for 
example, environmental or genetic) and the clinical syn­
drome (the phenotype). Intermediate phenotypes may 
provide insight into the mechanisms underlying the dis­
ease, and thereby give greater confidence for successful 
drug targeting. Nevertheless, one of the major challenges 
is to map and/or align intermediate phenotypes onto spe­
cific symptoms of schizophrenia, and to determine which 
of those intermediate phenotypes are most predictive for 
remediation by drugs.
Here, we review evidence from neuronal circuitry­
based imaging and electrophysiological approaches to 
discuss how the application of these strategies in preclini­
cal models is showing signs of success for future drug dis­
covery. We also argue that combining these approaches 
into integrated models will enable us to accelerate the 
drug discovery process. 
Imaging the dysfunctional brain
Extensive structural (diffusion tension imaging) and 
functional brain imaging studies such as positron emis­
sion tomography (PET) and functional magnetic reso­
nance imaging (fMRI) have provided clear evidence for 
abnormalities in schizophrenia (FIG. 2). Altered activity 
in the prefrontal cortex has been correlated with various 
cognitive deficits and can be manifested as hypofrontality 
(reduced cerebral blood flow and metabolism) or hyper­
frontality (increased cerebral blood flow and metabolism), 
depending on the task that the patient is asked to com­
plete. The current view is that dysfunction of the prefron­
tal cortex in patients with schizophrenia is more complex 
than simply showing ‘increased’ or ‘decreased’ activity81, 
and that either hypo­ or hyperfrontality may manifest, 
both of which represent prefrontal cortex inefficiency82. 
Of course, the prefrontal cortex does not function in 
isolation from other regions of the brain, and dynamic 
interactions with other neural systems are crucial for infor­
mation processing and the manifestation of symptoms. 
Measuring how neurons communicate with each other in 
a dynamic way, at the regional level and in terms of local 
circuitry, has — until recently — been a major challenge.
Table 3 | Drug reversal studies in genetically modified mice exhibiting schizophrenia-related behavioural deficits 
Gene Genetic 
modification
PPI impairment Hyperlocomotor 
activity 
Forced swim 
test
Sociability 
or social 
novelty
Latent 
inhibition 
deficit
Refs
Disc1 L100P (ENU 
mutant) 
Partial reversal by haloperidol 
and clozapine; reversal 
with rolipram (a PDE4B 
inhibitor) and with combined 
subthreshold doses of rolipram 
and a GSK3 inhibitor (TDZD-8)
Reversed by 
haloperidol  
and clozapine as well  
as with combined 
subthreshold doses of 
rolipram and TDZD-8
ND (mutant 
mice 
unaffected)
ND  
(mutant mice 
unaffected)
Reversed by 
haloperidol 
and 
clozapine
69,70, 
181
Disc1 Q31L (ENU 
mutant)
Reversed by bupropion and 
TDZD-8 but not by clozapine, 
haloperidol or rolipram
ND (locomotor activity 
unaffected in mutant 
mice)
Reversed by 
TDZD-8 and 
bupropion but 
not by rolipram
Reversed by 
TDZD-8
Not reversed 
by clozapine
69,70
Disc1 In utero 
Disc1 shRNA 
knockdown
Reversed by clozapine ND (locomotor activity 
unaffected by Disc1 
knockdown)
ND (unaffected 
by Disc1 
knockdown) 
ND ND 140 
Nrg1 Nrg1+/– type III 
knockout mice 
(CRD isoform)
Reversed by chronic nicotine 
administration
ND ND ND ND 146
Nrg1 Nrg1+/– knockout 
mice
Not reversed by clozapine Reversed by clozapine ND ND ND 145
Erbb4 Erbb2/b4–/– CNS 
knockout mice 
Reversed by clozapine ND ND ND ND 149
Akt1 Akt1–/– 
knockout mice
Female knockout mice exhibit 
PPI deficits; partial reversal by 
8-OH DPAT (a 5-HT
1A
 receptor 
agonist) and SB21673 (a GSK3 
inhibitor) but not by raclopride 
or clozapine 
ND ND ND ND 174
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One limiting factor in elucidating altered brain func­
tioning at a systems level has been the limited applica­
tion of available computational modelling algorithms to 
translational brain imaging data. For example, although 
algorithms aimed at elucidating alterations in regional 
and neural systems connectivity have long been used in 
clinical brain imaging83–85, they have only been applied to 
a limited degree in a preclinical context86.
The application of techniques to measure the func­
tional connectivity of brain regions to preclinical imaging 
data and drug discovery is in its infancy. Recently, we 
applied87 partial least squares regression to data generated 
from 2­deoxyglucose (2­DG) imaging to investigate the 
functional connectivity between regions of the brain in 
rats treated with subchronic doses of PCP. 2­DG imaging, 
which is broadly equivalent to PET imaging in humans, 
has been widely used to investigate the effects of diverse 
experimental manipulations (for example, pharmaco­
logical and genetic manipulation) on function­related 
changes in regional glucose use. Importantly, this study 
revealed schizophrenia­related alterations in the func­
tional connectivity of the prefrontal cortex with other 
regions of the brain, and also confirmed the previously 
established hypofrontality and hypometabolism in the 
reticular thalamus following repeated PCP treatment88.
A key advance is the integration of CNTRICS­
approved cognitive behavioural measures with brain 
imaging approaches. Our study87 was the first of its kind 
to demonstrate that modafinil restores PCP­induced def­
icits in the ASST; in parallel, it also restores PCP­induced 
hypofrontality and enhances the functional connectiv­
ity of the prefrontal cortex with the locus co eruleus. 
These findings closely align with clinical imaging and 
cognitive studies of modafinil89–91, and demonstrate the 
forward and reverse translational relevance of these 
two approaches. Hence, combining these translational 
behavioural and imaging methodologies with a validated 
disease model88,92,93 provides a powerful means of gain­
ing a mechanistic understanding of drug action at the 
level of neural circuitry, and for progressing new targets 
through the drug discovery process.
A further advance will be the adoption of algorithms 
from network science to understand how the properties 
of brain networks are affected in disease models that have 
Table 3 (cont.) | Drug reversal studies in genetically modified mice exhibiting schizophrenia-related behavioural deficits 
Gene Genetic 
modification
PPI impairment Hyperlocomotor activity Forced 
swim test
Sociability 
or social 
novelty
Latent 
inhibition 
deficit
Refs
Erbb4 PV-Cre; 
Erbb4–/– 
knockout mice
Attenuated by diazepam ND ND ND ND 77
Chromosome 
22q11 
deletion
Overexpression 
of four genes 
from human 
chromosome 
22q11
Haloperidol and clozapine 
(at acute and chronic 
doses) restore sensitized 
hyperactivity
ND ND ND ND 182
Grin1 (NR1) Grin1–/– 
knockdown
Haloperidol, quetiapine, 
olanzapine and risperidone 
enhance PPI in wild-type 
and Grin1–/– mice; 
inconsistent results with 
clozapine between studies
Attenuated by clozapine 
and olanzapine; conflicting 
results with haloperidol
ND Restored 
by 
clozapine 
but not by 
haloperidol
ND 163, 
183–185
Grin2 (NR2) Grin2–/– 
knockout mice 
ND Attenuated by haloperidol 
and risperidone
ND ND ND 165
Gria1 (AMPA 
receptor 1)
Gria1–/– 
knockout mice
ND Attenuated by haloperidol 
and lithium but not by 
SB216763
ND ND ND 66,169
Grm1 
(mGluR1)
Grm1–/– 
knockout mice
PPI deficits reversed 
by lamotrigine but not 
raclopride
ND ND ND ND 186
Grm5 
(mGluR5)
Grm5–/– 
knockout mice
PPI deficits not reversed by 
lamotrigine, clozapine or 
raclopride
ND ND ND ND 187
Slc6a3 (DAT) Slc6a3–/– 
knockout mice
Reversed by D2- and 
5-HT
2A
receptor antagonists, 
fluoxetine, raclopride, 
clozapine and quetiapine; 
no effect of D1 receptor 
antagonist SCH23390
Inhibited by raclopride, 
SCH23390,5-HT2A receptor 
antagonists, 5-HT receptor 
agonists, ampakines, 
nicotine, lithium, valproate 
and GSK3β inhibitors
ND ND ND 75,76
5-HT
1A
, 5-hydroxytryptamine receptor 1A; 8-OH DPAT, 7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid; CNS, central nervous system; D1, dopamine receptor D1; DISC1, disrupted in schizophrenia 1; ENU, N-ethyl-N-nitrosourea; GRIA1, AMPA 
receptor 1; GRIN1, NMDA receptor subunit NR1; GSK3, glycogen synthase kinase 3; mGluR1, metabotropic glutamate receptor 1; ND, not determined; NMDA, 
N-methyl-d-aspartate; NRG1, neuregulin 1; PDE4B, phosphodiesterase 4B; PPI, prepulse inhibition; PV, parvalbumin; shRNA, short hairpin RNA; SLC6A3, solute 
carrier 6 member 3 (dopamine transporter).
Partial least squares 
regression 
A multivariate modelling 
method that is useful for 
quantitatively defining  
the relationship between 
several collinear predictors  
and response variables.  
In neuroimaging it has been  
used to define functional 
connectivity between  
regions of the brain.
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Thalamus
Hippocampus
Thalamus
Hippocampus
Prefrontal
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construct validity. These algorithms enable the objective 
characterization of alterations in functional brain network 
connectivity on multiple scales: ranging from regional 
alterations to alterations in neural systems as well as altera­
tions that are seen in global network properties94. Exciting 
findings from this research demonstrate that the human 
brain has properties in common with other complex net­
works (such as the Internet) that support an efficient trans­
fer of information. Brain imaging studies (such as fMRI) 
have revealed that these small­world properties are altered 
in schizophrenia95–97. These abnormalities in the organiza­
tion of brain networks are consistent with aberrant brain 
development but as yet it is unclear how networks form 
during development, and when and how they become per­
turbed in individuals who are at a high risk of developing 
schizophrenia.
These algorithms have been applied to functional 
brain imaging data obtained from a rodent subchronic 
PCP treatment model, and they demonstrate that the 
alterations in functional brain network structure at a 
global scale in this translational model are similar to those 
observed in patients with schizophrenia98. 
The application of these technologies to drug discov­
ery is eagerly awaited. The current idea that drugs act in 
particular regions of the brain is overly simplistic, and 
it is unlikely that the clinical efficacy of all drugs can be 
established solely based on their ability to reverse regional 
deficits in cerebral metabolism. The ability to understand 
how a drug is able to reconstruct network activity in a 
dysfunctional brain offers immense promise for identi­
fying compounds that are likely to be successful in the 
clinic. Implementing this approach in preclinical studies, 
using models of construct validity, is likely to reduce attri­
tion in late stages of drug development. 
Mechanisms of dysfunctional network activity
Communication between areas of the brain is manifested 
in patterns of synchronized and desynchronized neu­
ronal activity that can be detected by local field potentials 
and electroencephalogram recordings.
Of particular interest to schizophrenia are neural 
oscillations in the θ (4–7 Hz) and γ (30–100 Hz) fre­
quencies. Importantly, fast spiking parvalbumin­positive 
GABAergic interneurons have been shown to be central 
to the mechanisms of θ­ and γ­generation99–101. Hence, 
dysfunction of parvalbumin­positive interneurons 
could potentially cause dysfunctional network activity. 
Importantly, in schizophrenia there is both pathological 
and electrophysiological evidence to support the disrup­
tion of GABAergic cells. Studies have shown that the 
expression of GABAergic markers, including parval­
bumin in post­mortem brain samples41, is reduced in 
schizo phrenia; clinical studies have also shown alterations 
in the characteristics of spontaneous γ­ and θ­oscillations 
in the prefrontal and temporal cortices, which have been 
correlated with several symptoms of schizophrenia102,103. 
However, the extent to which impairments in GABAergic 
interneurons contribute to the clinical symptoms of 
schizophrenia remains to be established.
Deficits in GABAergic interneurons have been 
demonstrated in NMDA receptor models and genetic 
models relevant to schizophrenia104. The expression of 
GABAergic markers such as parvalbumin is reduced fol­
lowing subchronic and chronic PCP treatment as well as 
in a Disc1­transgenic mouse model of schizophrenia73,88. 
Interestingly, clozapine (but not haloperidol) reverses 
the parvalbumin deficit induced by repeated PCP treat­
ment, but clozapine does not rescue the parallel changes 
in hypofrontality. This suggests that hypofrontality can be 
sustained in the absence of GABAergic basket cell and/
or chandelier cell dysfunction in the prefrontal cortex. 
In future studies it would be beneficial to determine 
whether γ­ and θ­oscillations are disrupted in these 
genetic and pharmacological models and, if so, to examine 
the ability of drugs to rescue these deficits. 
Encouragingly, mice that model deletion of human 
chromosome 22q11 have deficits in prefrontal–hippo­
campal synchrony that appear to be related to perfor­
mance in a working memory task105, but drug reversal 
studies have not yet been conducted. The importance of 
Figure 2 | Dysfunctional connectivity in schizophrenia. Aberrant activity in both rodent models of the disease (left 
panel) and in patients (right panel) is centred on prefrontal–hippocampal–thalamic networks.
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examining synchrony between key regions of the brain 
and neural circuits, particularly their relationship to 
behaviour, cannot be understated. Of particular inter­
est is the examination of thalamocortical synchrony and 
activity in the cingulate cortex and the reticular nucleus 
of the thalamus.
In summary, recent technological advances have 
enabled us to gain greater insight into the cellular mech­
anisms that underlie the network dysfunction that is 
relevant to schizophrenia. Furthermore, the ability to 
measure network oscillations using next­generation 
electrophysiology in freely moving and behaving ani­
mals provides us with more sophisticated methods to 
investigate brain dysfunction in disease models that 
exhibit construct validity. This approach could prove to 
be an effective strategy for identifying novel therapeutic 
agents to treat schizophrenia.
Integrating genetic and neural systems data
Thousands of genes regulate the formation of brain 
circuitry during development, acting in a complex and 
synergistic fashion to govern the expression of neuropsy­
chiatric phenotypes. It is probable that many genetic 
mutations converge on particular neural circuitry that 
is related to defined symptoms.
Imaging genetics is an emerging field that combines 
the analysis of genetic variation with quantification of 
structural and functional abnormalities in the live human 
brain. The application of neuroimaging techniques, fre­
quently in conjunction with a cognitive test, is produc­
ing intriguing evidence that candidate genes may affect 
network function in schizophrenia106,107. Several candi­
date genes have been linked to structural and functional 
changes in the brain (measured by MRI) that are rele­
vant to schizophrenia; these include the genes enoding 
catechol­O­methyltransferase (COMT)108, metabotropic 
glutamate receptor 3 (GRM3)109, potassium voltage­gated 
channel subfamily H member 2 (KCNH2)110, DISC1 
(REF. 111), glutamate decarboxylase 1 (GAD1; also known 
as GAD67)112, NRG1 (REF. 113) and zinc finger pro­
tein 804A (ZNF804A)114. 
These studies are often conducted in healthy indi­
viduals, in whom phenotypic variability is likely to be 
lower than in patients with schizophrenia. In an innova­
tive study, this has been extended to genome­wide SNP 
analysis, using individuals stratified by fMRI as a quan­
titative phenotype. This approach has revealed a small 
number of genes with a potential role in the activation 
of the prefrontal cortex115,116. 
However, questions remain over the validity of these 
studies owing to their small sample sizes, lack of repli­
cation and the genetic heterogeneity of the individuals 
enrolled in the study. The influences of genetic varia­
tion on brain structure in the genes studied to date is 
thought to be subtle117,118. 
In summary, the influence of genetics on the devel­
opment of schizophrenia may be most clearly identified 
using a combination of imaging and cognitive studies. 
This in turn suggests that translational animal mod­
els, particularly those involving a genetic component, 
might advantageously adopt equivalent methodological 
paradigms to provide intermediate phenotypes and 
biomarkers that can be used in drug discovery and to 
monitor drug efficacy in humans. 
Conclusion 
The discovery of drugs for treating schizophrenia needs 
to be informed by knowledge of the causes of this com­
plex brain disorder. Emerging genetic, physiological, 
cognitive and systems­based imaging evidence of schiz­
ophrenia, in parallel with the emergence of clinically 
relevant preclinical translational assays, means that we 
are moving to a position of strength to advance drug 
discovery. Through these recent advances, scientists are 
now able to integrate this knowledge, placing us in a 
much stronger position to develop potential biomark­
ers for diagnosis and to tackle drug discovery from an 
informed translational perspective.
Major technological and analytical advances are now 
providing scientists with the opportunity to gain greater 
insight into the complex genetic architecture and the 
true nature of brain dysfunction at a systems level in 
schizophrenia. The integration of genetic information 
obtained from genome­wide association studies and 
other studies will provide new insight into the ways 
in which neural circuitry and downstream biological 
pathways are altered by candidate genes. This informa­
tion paves the way for novel target identification and 
for the development of models with improved construct 
validity for drug development. Rather than relying on 
serendipitous strategies for target discovery, rational 
target design strategies can be implemented based on 
an enhanced understanding of how genetic pathways 
affect biological systems.
A recurring theme throughout this Review is that for 
a compound to be considered as a strong clinical can­
didate it should demonstrate efficacy in translationally 
relevant assays in models with high construct validity. 
Failures of previous strategies have arisen largely because 
of the persistence of using high­throughput, simple 
behavioural end points (which are of no translational 
value) in models that are of questionable relevance to 
the disease. 
We now have a range of translational cognitive assays 
(for example, ASST and 5­CSRTT, with others being 
developed) that can be used for assessing compounds, 
as well as advanced imaging and electrophysiological 
methods that can inform on drug activity at the level of 
neural circuitry. We also have improved models based 
on genetic and environmental risk factors. To ensure 
optimal translation, these genetic models should have 
a strong molecular relationship with the genetic factors 
identified in patients with schizophrenia, and modelling 
of environmental risk factors should be appropriately 
timed during the developmental process. 
Integration of genetic models and assays with classical 
pharmacological approaches offers great opportunities 
for drug discovery in schizophrenia and in neuropsy­
chiatry as a whole. The preclinical validation of novel 
compounds must be aligned more closely with the clini­
cal situation. This should include chronic drug admin­
istration and, for cognition­enhancing compounds that 
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are intended to be used as add­on treatments, preclini­
cal validation should also be conducted during chronic 
antipsychotic drug treatment.
In conclusion, emerging genetic, cellular and brain 
imaging evidence is enabling the pieces of the schizo­
phrenia jigsaw to be assembled. We now have the 
armoury, so the time is ripe to put aside the former inef­
fective approaches for schizophrenia drug discovery and 
replace them with high­quality integrated translational 
neuroscience programmes. Although this will often 
mean losing the seductively high throughput of simple 
assays in simple models, it is our hope that the advanced 
understanding of disease pathophysiology gained through 
these truly translational approaches will compensate, 
through the rational selection of empirically identified 
therapeutic targets.
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